STXBP1 Encephalopathy With Epilepsy
7
4
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Gait in Rare Diseases
A Multicentric European Study to Promote Clinical Trial Readiness for STXBP1-related Disorders
STXBP1 and SYNGAP1 Related Disorders Natural History Study
Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes